Mammalian models of bone sarcomas
暂无分享,去创建一个
[1] T. Fujiwara,et al. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma , 2020, Cancer Immunology, Immunotherapy.
[2] C. H. Nielsen,et al. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis , 2020, Scientific Reports.
[3] E. Kleinerman,et al. Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma , 2020, International journal of cancer.
[4] M. Chang,et al. A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression , 2020, Nature Communications.
[5] Nicholas J. Slipek,et al. Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma , 2020, Molecular Cancer Therapeutics.
[6] M. Durante,et al. Reduction of lung metastases in a mouse osteosarcoma model treated with carbon ions and immune checkpoint inhibitors. , 2020, International journal of radiation oncology, biology, physics.
[7] Lang Li,et al. Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma , 2020, Cancers.
[8] B. Teicher,et al. Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium , 2020, Pediatric hematology and oncology.
[9] B. Teicher,et al. Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium , 2020, Pediatric blood & cancer.
[10] Haydee M Torres,et al. Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway , 2020, Oncotarget.
[11] D. Reed,et al. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma , 2020, International journal of cancer.
[12] Yuanzhong Wu,et al. Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma , 2020, Theranostics.
[13] A. Yamamoto,et al. Promising abscopal effect of combination therapy with thermal tumour ablation and intratumoural OK-432 injection in the rat osteosarcoma model , 2020, Scientific Reports.
[14] C. Isella,et al. Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights , 2020, Cancers.
[15] P. Houghton,et al. Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium , 2020, Pediatric blood & cancer.
[16] S. Dry,et al. Patient-derived orthotopic xenograft models of sarcoma. , 2020, Cancer letters.
[17] M. Heymann,et al. Bone sarcomas in the immunotherapy era , 2020, British journal of pharmacology.
[18] M. Martano,et al. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models. , 2019, Veterinary and comparative oncology.
[19] I. Alferiev,et al. Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS‐2/8 Chondrosarcoma Cells , 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[20] D. Haussler,et al. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design , 2019, Cell reports.
[21] B. Fuchs,et al. The miR‐143/145 Cluster, a Novel Diagnostic Biomarker in Chondrosarcoma, Acts as a Tumor Suppressor and Directly Inhibits Fascin‐1 , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] J. Webster,et al. Applications and considerations for the use of genetically engineered mouse models in drug development , 2019, Cell and Tissue Research.
[23] G. R. Ordóñez,et al. New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth , 2019, Journal of clinical medicine.
[24] D. Heymann,et al. Jaw osteosarcoma models in mice: first description , 2019, Journal of Translational Medicine.
[25] R. Oyama,et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1 , 2019, Human Cell.
[26] Shing-Hwa Liu,et al. MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis , 2018, International journal of molecular sciences.
[27] Marcus R. Breese,et al. Genome-Informed Targeted Therapy for Osteosarcoma. , 2018, Cancer discovery.
[28] P. Houghton,et al. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling , 2018, Clinical Cancer Research.
[29] M. Heymann,et al. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy , 2018, Journal of bone oncology.
[30] S. Kizaka-Kondoh,et al. Novel lymphoid enhancer‐binding factor 1‐cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs , 2018, Cancer science.
[31] M. Symons,et al. Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model of Metastasis: A Mouse Osteosarcoma Model , 2018, Clinical orthopaedics and related research.
[32] A. Boccaccini,et al. Proangiogenic effects of tumor cells on endothelial progenitor cells vary with tumor type in an in vitro and in vivo rat model , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] C. Chenu,et al. Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A , 2018, Scientific Reports.
[34] J. M. Guimarães,et al. PATIENT-DERIVED XENOGRAFTS AS A PRECLINICAL MODEL FOR BONE SARCOMAS , 2018, Acta ortopedica brasileira.
[35] D. Heymann,et al. Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations , 2018, Journal of bone oncology.
[36] M. Heymann,et al. Biology of Bone Sarcomas and New Therapeutic Developments , 2017, Calcified Tissue International.
[37] Jinhu Liu,et al. Redox‐sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[38] T. Nakagawa,et al. Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model. , 2017, Research in veterinary science.
[39] D. Heymann,et al. Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. , 2017, Cancer letters.
[40] B. Fuchs,et al. Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models , 2017, International journal of cancer.
[41] T. Nakagawa,et al. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines. , 2016, Veterinary journal.
[42] L. Donehower,et al. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential , 2016, BMC Cancer.
[43] G. Mælandsmo,et al. Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma , 2016, PloS one.
[44] Kevin B. Jones,et al. Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis , 2016, Disease Models & Mechanisms.
[45] M. Heymann,et al. Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.
[46] K. Condon,et al. Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats , 2016, PloS one.
[47] D. Surdez,et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model , 2016, Oncotarget.
[48] D. Saur,et al. A porcine model of osteosarcoma , 2016, Oncogenesis.
[49] Kyle W. Jackson,et al. An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis , 2015, Clinical & Experimental Metastasis.
[50] Kevin B. Jones,et al. Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency , 2015, The Journal of pathology.
[51] D. Heymann,et al. BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma , 2015, International journal of cancer.
[52] P. Yuan,et al. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression , 2014, Oncogene.
[53] Kevin B. Jones,et al. The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse , 2014, Oncogene.
[54] B. Dawson,et al. Notch activation as a driver of osteogenic sarcoma. , 2014, Cancer cell.
[55] D. Meyerholz,et al. Development and translational imaging of a TP53 porcine tumorigenesis model. , 2014, The Journal of clinical investigation.
[56] Ranim R. Mira,et al. Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model. , 2014, American journal of cancer research.
[57] David Sidransky,et al. Patient-derived xenografts for individualized care in advanced sarcoma , 2014, Cancer.
[58] Frederic Blanchard,et al. Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models , 2014, PloS one.
[59] A. Chalk,et al. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. , 2013, Bone.
[60] F. Verrecchia,et al. A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis. , 2013, European journal of cancer.
[61] M. Heymann,et al. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance , 2013, Laboratory Investigation.
[62] M. Mochizuki,et al. Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice. , 2012, Veterinary and comparative oncology.
[63] O. Delattre,et al. Oncostatin M is a growth factor for Ewing sarcoma. , 2012, The American journal of pathology.
[64] J. Blay,et al. Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model , 2012, PloS one.
[65] D. Jong,et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT , 2012, Oncogene.
[66] A. Llombart‐Bosch,et al. Characterization of a New Human Cell Line (CH-3573) Derived from a Grade II Chondrosarcoma with Matrix Production , 2012, Pathology & Oncology Research.
[67] J. Chezal,et al. Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma. , 2012, Cancer biotherapy & radiopharmaceuticals.
[68] G. Moriceau,et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. , 2010, Cancer research.
[69] A. Constantinesco,et al. Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. , 2010, Translational oncology.
[70] O. Delattre,et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. , 2010, Cancer research.
[71] T. Triche,et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. , 2010, The Journal of clinical investigation.
[72] J. Monteil,et al. 18F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model , 2009, Journal of Nuclear Medicine.
[73] P. Lin,et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. , 2008, Cancer research.
[74] M. Bouxsein,et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage , 2008, Proceedings of the National Academy of Sciences.
[75] F. Alt,et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.
[76] Mimi Kim,et al. Preclinical Analysis of Tasidotin HCl in Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, and Osteosarcoma , 2007, Clinical Cancer Research.
[77] C. Nanni,et al. Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.
[78] D. Heymann,et al. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival , 2006, International journal of cancer.
[79] M. Heymann,et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.
[80] J. Thiery,et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. , 2005, Bone.
[81] E. Kleinerman,et al. Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo , 2005, Clinical Cancer Research.
[82] D. Heymann,et al. Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. , 2002, Histology and histopathology.
[83] H. Jürgens,et al. Establishment of an In Vivo Model for Pediatric Ewing Tumors by Transplantation into NOD/ scid Mice , 2001, Pediatric Research.
[84] A. Dietz,et al. Production and characterization of canine osteosarcoma cell lines that induce transplantable tumors in nude mice. , 1998, American journal of veterinary research.
[85] T. Triche,et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.
[86] E. Wagner,et al. Osteoblasts are target cells for transformation in c-fos transgenic mice , 1993, The Journal of cell biology.
[87] K. Gomi,et al. ANTITUMOR EFFECT OF HUMAN RECOMBINANT INTERFERON-γ AND -β AGAINST HUMAN OSTEOSARCOMA TRANSPLANTED INTO NUDE MICE , 1986 .